JaeKi Min

Title: JaeKi Min: Innovator in Pharmaceutical Chemistry

Introduction

JaeKi Min is a notable inventor based in Yongin, South Korea. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of compounds that can aid in the treatment of metabolic disorders.

Latest Patents

JaeKi Min holds a patent for "Amide derivatives for GPR119 agonist." This invention relates to novel amide derivatives, their stereoisomers, or pharmaceutically acceptable salts. The patent also includes methods for preparing these compounds and pharmaceutical compositions that comprise them. The novel amide derivatives have been identified as effective GPR119 agonists, which can be utilized in the treatment of metabolic disorders, including diabetes mellitus, especially type II diabetes, and related conditions.

Career Highlights

JaeKi Min is currently associated with Chong Kun Dang Pharmaceutical Corporation, where he continues to innovate and contribute to the pharmaceutical industry. His work focuses on developing new therapeutic agents that can improve patient outcomes in metabolic health.

Collaborations

JaeKi Min collaborates with talented professionals in his field, including Younghue Han and Dohoon Kim. Their combined expertise enhances the research and development efforts at Chong Kun Dang Pharmaceutical Corporation.

Conclusion

JaeKi Min's contributions to pharmaceutical chemistry, particularly through his patent on amide derivatives, highlight his role as an innovator in the treatment of metabolic disorders. His ongoing work at Chong Kun Dang Pharmaceutical Corporation continues to pave the way for advancements in healthcare.